Logo image of KURA

KURA ONCOLOGY INC (KURA) Stock Overview

NASDAQ:KURA - US50127T1097 - Common Stock

7.9 USD
-0.17 (-2.11%)
Last: 8/29/2025, 8:00:02 PM
8.15 USD
+0.25 (+3.16%)
After Hours: 8/29/2025, 8:00:02 PM

KURA Key Statistics, Chart & Performance

Key Statistics
52 Week High21.57
52 Week Low5.41
Market Cap685.72M
Shares86.80M
Float84.89M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.26
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO11-05 2015-11-05
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


KURA short term performance overview.The bars show the price performance of KURA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

KURA long term performance overview.The bars show the price performance of KURA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of KURA is 7.9 USD. In the past month the price increased by 31.23%. In the past year, price decreased by -62.49%.

KURA ONCOLOGY INC / KURA Daily stock chart

KURA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About KURA

Company Profile

KURA logo image Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.

Company Info

KURA ONCOLOGY INC

12730 High Bluff Drive, Suite 400

San Diego CALIFORNIA 92130 US

CEO: Troy E. Wilson

Employees: 192

KURA Company Website

KURA Investor Relations

Phone: 18585008800

KURA ONCOLOGY INC / KURA FAQ

What is the stock price of KURA ONCOLOGY INC today?

The current stock price of KURA is 7.9 USD. The price decreased by -2.11% in the last trading session.


What is the ticker symbol for KURA ONCOLOGY INC stock?

The exchange symbol of KURA ONCOLOGY INC is KURA and it is listed on the Nasdaq exchange.


On which exchange is KURA stock listed?

KURA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KURA ONCOLOGY INC stock?

21 analysts have analysed KURA and the average price target is 25.93 USD. This implies a price increase of 228.16% is expected in the next year compared to the current price of 7.9. Check the KURA ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KURA ONCOLOGY INC worth?

KURA ONCOLOGY INC (KURA) has a market capitalization of 685.72M USD. This makes KURA a Small Cap stock.


How many employees does KURA ONCOLOGY INC have?

KURA ONCOLOGY INC (KURA) currently has 192 employees.


What are the support and resistance levels for KURA ONCOLOGY INC (KURA) stock?

KURA ONCOLOGY INC (KURA) has a support level at 5.55. Check the full technical report for a detailed analysis of KURA support and resistance levels.


Is KURA ONCOLOGY INC (KURA) expected to grow?

The Revenue of KURA ONCOLOGY INC (KURA) is expected to grow by 895.94% in the next year. Check the estimates tab for more information on the KURA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy KURA ONCOLOGY INC (KURA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KURA ONCOLOGY INC (KURA) stock pay dividends?

KURA does not pay a dividend.


When does KURA ONCOLOGY INC (KURA) report earnings?

KURA ONCOLOGY INC (KURA) will report earnings on 2025-11-05, after the market close.


What is the Price/Earnings (PE) ratio of KURA ONCOLOGY INC (KURA)?

KURA ONCOLOGY INC (KURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.26).


What is the Short Interest ratio of KURA ONCOLOGY INC (KURA) stock?

The outstanding short interest for KURA ONCOLOGY INC (KURA) is 9.36% of its float. Check the ownership tab for more information on the KURA short interest.


KURA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to KURA. When comparing the yearly performance of all stocks, KURA is a bad performer in the overall market: 85.17% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

KURA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to KURA. KURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KURA Financial Highlights

Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -2.26. The EPS decreased by -1.35% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.89%
ROE -64.54%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%-27.12%
Sales Q2Q%N/A
EPS 1Y (TTM)-1.35%
Revenue 1Y (TTM)N/A

KURA Forecast & Estimates

21 analysts have analysed KURA and the average price target is 25.93 USD. This implies a price increase of 228.16% is expected in the next year compared to the current price of 7.9.

For the next year, analysts expect an EPS growth of -27% and a revenue growth 895.94% for KURA


Analysts
Analysts82.86
Price Target25.93 (228.23%)
EPS Next Y-27%
Revenue Next Year895.94%

KURA Ownership

Ownership
Inst Owners92.91%
Ins Owners1.18%
Short Float %9.36%
Short Ratio5.39